Fig. 7.

PAQR5 attenuates the tumorigenicity of ccRCC in vivo. A Representative image of the tumors harvested from the control group and the PAQR5 overexpression group is shown in the left panel. B The tumor volume changes in the control group and the PAQR5 overexpression group were measured and calculated every four days. C The tumor weight in the control group and the PAQR5 overexpression group was determined after the tumors were harvested at the end of the experiment. D The expression levels of PAQR5, P-STAT3, and STAT3 were evaluated by western blotting analysis. β-actin was used as an internal control. E Immunohistochemistry was used to detect the expression of PAQR5, P-STAT3, and Ki-67. The scale bar represents 50 μm. F An illustration of how PAQR5 inhibits cell proliferation, invasion, migration, and tumorigenicity in ccRCC by suppressing the JAK-STAT3 signaling pathway. **P < 0.01, ***P < 0.001